Tyche Wealth Partners LLC Purchases New Position in Coherus BioSciences, Inc. (NASDAQ:CHRS)

Tyche Wealth Partners LLC acquired a new position in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 215,902 shares of the biotechnology company’s stock, valued at approximately $719,000. Tyche Wealth Partners LLC owned about 0.19% of Coherus BioSciences at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of CHRS. Eagle Bay Advisors LLC lifted its holdings in shares of Coherus BioSciences by 136.1% during the 2nd quarter. Eagle Bay Advisors LLC now owns 3,891 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 2,243 shares in the last quarter. Captrust Financial Advisors lifted its stake in Coherus BioSciences by 1,461.0% in the first quarter. Captrust Financial Advisors now owns 2,404 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 2,250 shares in the last quarter. Dorsey & Whitney Trust CO LLC acquired a new position in shares of Coherus BioSciences in the third quarter valued at approximately $39,000. Princeton Global Asset Management LLC bought a new stake in shares of Coherus BioSciences during the third quarter worth $39,000. Finally, Federated Hermes Inc. raised its holdings in shares of Coherus BioSciences by 55.0% during the third quarter. Federated Hermes Inc. now owns 4,223 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 1,498 shares during the period. Institutional investors and hedge funds own 72.82% of the company’s stock.

Coherus BioSciences Stock Performance

NASDAQ CHRS traded up $0.04 during trading hours on Wednesday, hitting $2.19. 123,441 shares of the company traded hands, compared to its average volume of 3,883,745. The business’s 50-day moving average is $2.41 and its 200-day moving average is $2.55. Coherus BioSciences, Inc. has a twelve month low of $1.43 and a twelve month high of $8.34.

Coherus BioSciences (NASDAQ:CHRS) last released its quarterly earnings data on Wednesday, March 13th. The biotechnology company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.39). The firm had revenue of $91.52 million during the quarter, compared to the consensus estimate of $105.30 million. Analysts predict that Coherus BioSciences, Inc. will post -0.56 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on CHRS. HC Wainwright reduced their target price on shares of Coherus BioSciences from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, March 20th. Truist Financial decreased their price objective on Coherus BioSciences from $12.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday, January 23rd. Finally, Robert W. Baird reduced their price target on Coherus BioSciences from $11.00 to $9.00 and set an “outperform” rating for the company in a research report on Tuesday, January 23rd. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $9.29.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.